William Blair Initiates Coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX)

Equities researchers at William Blair assumed coverage on shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) in a report issued on Monday, Marketbeat.com reports. The brokerage set an “outperform” rating on the stock.

Several other analysts have also weighed in on the stock. HC Wainwright lowered their price objective on shares of Eupraxia Pharmaceuticals from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, March 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Thursday, January 22nd. Wall Street Zen downgraded shares of Eupraxia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, February 21st. Zacks Research lowered shares of Eupraxia Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Tuesday, March 17th. Finally, Cantor Fitzgerald increased their price objective on shares of Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the stock an “overweight” rating in a research report on Thursday, January 15th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $15.00.

Eupraxia Pharmaceuticals Price Performance

NASDAQ EPRX opened at $6.89 on Monday. The stock has a market capitalization of $247.76 million, a P/E ratio of -6.69 and a beta of 1.27. The business has a 50 day simple moving average of $8.21 and a 200 day simple moving average of $6.94. Eupraxia Pharmaceuticals has a one year low of $2.68 and a one year high of $9.32.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last issued its quarterly earnings results on Thursday, March 19th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.21). Equities analysts expect that Eupraxia Pharmaceuticals will post -0.67 earnings per share for the current year.

Institutional Trading of Eupraxia Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Vivo Capital LLC bought a new position in shares of Eupraxia Pharmaceuticals during the third quarter valued at about $7,965,000. Ally Bridge Group NY LLC bought a new stake in Eupraxia Pharmaceuticals in the 3rd quarter worth about $5,398,000. Ikarian Capital LLC purchased a new stake in Eupraxia Pharmaceuticals in the 4th quarter valued at about $4,606,000. Squadron Capital Management LLC bought a new position in shares of Eupraxia Pharmaceuticals during the 4th quarter worth approximately $3,775,000. Finally, Velan Capital Investment Management LP bought a new position in shares of Eupraxia Pharmaceuticals during the 3rd quarter worth approximately $2,077,000.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.